Last reviewed · How we verify
Paroxetine+Lamotrigine
This combination pairs a selective serotonin reuptake inhibitor (paroxetine) with an anticonvulsant mood stabilizer (lamotrigine) to enhance serotonergic neurotransmission while modulating glutamate and sodium channels.
This combination pairs a selective serotonin reuptake inhibitor (paroxetine) with an anticonvulsant mood stabilizer (lamotrigine) to enhance serotonergic neurotransmission while modulating glutamate and sodium channels. Used for Major depressive disorder, Bipolar disorder (depression and maintenance), Anxiety disorders.
At a glance
| Generic name | Paroxetine+Lamotrigine |
|---|---|
| Also known as | seroxat, lamictal |
| Sponsor | Ministry of Health & Welfare, Korea |
| Drug class | SSRI + anticonvulsant mood stabilizer combination |
| Target | Serotonin transporter (SERT); voltage-gated sodium channels; glutamate release modulation |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Paroxetine inhibits serotonin reuptake at the presynaptic terminal, increasing synaptic serotonin availability. Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, providing mood-stabilizing and neuroprotective effects. The combination is used to treat mood and anxiety disorders where monotherapy may be insufficient.
Approved indications
- Major depressive disorder
- Bipolar disorder (depression and maintenance)
- Anxiety disorders
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia or somnolence
- Rash (lamotrigine-related)
- Sexual dysfunction
- Weight changes
Key clinical trials
- Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Intervention Study for Individuals With Compulsive Sexual Behavior (NA)
- Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients (PHASE4)
- Lamotrigine Augmentation in Resistant Depression (NA)
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) (NA)
- Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paroxetine+Lamotrigine CI brief — competitive landscape report
- Paroxetine+Lamotrigine updates RSS · CI watch RSS
- Ministry of Health & Welfare, Korea portfolio CI